Compare IBEX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | ADCT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 484.4M |
| IPO Year | 2017 | 2019 |
| Metric | IBEX | ADCT |
|---|---|---|
| Price | $28.40 | $3.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $35.00 | $7.75 |
| AVG Volume (30 Days) | 110.3K | ★ 630.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.26 | ★ 30.86 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | $81,357,000.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | $66.49 |
| P/E Ratio | $17.25 | ★ N/A |
| Revenue Growth | 9.77 | ★ 14.85 |
| 52 Week Low | $22.63 | $1.14 |
| 52 Week High | $42.99 | $4.98 |
| Indicator | IBEX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 48.03 |
| Support Level | $28.26 | $3.34 |
| Resistance Level | $28.91 | $3.88 |
| Average True Range (ATR) | 0.79 | 0.20 |
| MACD | 0.29 | 0.01 |
| Stochastic Oscillator | 84.99 | 66.10 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).